BioCardia Inc Dossier
Qualitative Analysis
Business overview
BioCardia, Inc. (NASDAQ: BCDA) is a clinical-stage regenerative medicine company focused on developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. The company's therapeutic platforms include autologous and allogeneic cell therapies designed to address large unmet medical needs. Its lead product candidate is CardiAMP (BCDA-01), an autologous mononuclear cell therapy system currently in a confirmatory Phase III clinical trial (CardiAMP HF II) for ischemic heart failure with reduced ejection fraction (HFrEF). BioCardia also develops CardiALLO (BCDA-02), an allogeneic mesenchymal stem cell therapy in Phase II for ischemic heart failure, and PulmALLO (BCDA-03) for acute respiratory distress syndrome. Additionally, the company offers the Helix biotherapeutic delivery system, which provides minimally invasive targeted delivery of biologic agents directly to the heart muscle.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Prioritizing the regulatory submission to the Japanese Pharmaceutical and Medical Device Agency (PMDA) for market approval of CardiAMP Cell Therapy for ischemic heart failure with reduced ejection fraction (HFrEF) [1.1.1].
Expected impact: Could open up a significant market with high unmet medical need, targeting an estimated 20,000 patients annually in Japan.
Advancing patient enrollment in the confirmatory Phase 3 CardiAMP Heart Failure II trial in the United States.
Expected impact: Provides the necessary clinical validation and data to support potential premarket approval (PMA) with the FDA.
Actively seeking strategic partnerships and licensing deals around pipeline assets, including the Helix/Heart3D biotherapeutic delivery platform and the clinical allogeneic MSC platform.
Expected impact: Aims to secure non-dilutive funding, validate proprietary technology, and reduce cash burn.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides crucial, non-dilutive resources to support the clinical development of CardiAMP for heart failure, validating the science and covering operational costs for trial sites in Maryland [1.1.5].
Terms: Non-dilutive program support and grant funding.